Linked Life Data

18780829

Source:http://linkedlifedata.com/resource/pubmed/id/18780829

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18780829rdf:typepubmed:Citationlld:pubmed
pubmed-article:18780829lifeskim:mentionsumls-concept:C0936223lld:lifeskim
pubmed-article:18780829lifeskim:mentionsumls-concept:C0162638lld:lifeskim
pubmed-article:18780829lifeskim:mentionsumls-concept:C0334227lld:lifeskim
pubmed-article:18780829lifeskim:mentionsumls-concept:C0521447lld:lifeskim
pubmed-article:18780829lifeskim:mentionsumls-concept:C0069717lld:lifeskim
pubmed-article:18780829lifeskim:mentionsumls-concept:C0040649lld:lifeskim
pubmed-article:18780829lifeskim:mentionsumls-concept:C1514762lld:lifeskim
pubmed-article:18780829lifeskim:mentionsumls-concept:C0683598lld:lifeskim
pubmed-article:18780829lifeskim:mentionsumls-concept:C0279023lld:lifeskim
pubmed-article:18780829pubmed:issue3lld:pubmed
pubmed-article:18780829pubmed:dateCreated2008-11-13lld:pubmed
pubmed-article:18780829pubmed:abstractTextConstitutive activation of nuclear factor (NF)-kappaB is linked with the intrinsic resistance of androgen-independent prostate cancer (AIPC) to cytotoxic chemotherapy. Interleukin-8 (CXCL8) is a transcriptional target of NF-kappaB whose expression is elevated in AIPC. This study sought to determine the significance of CXCL8 signaling in regulating the response of AIPC cells to oxaliplatin, a drug whose activity is reportedly sensitive to NF-kappaB activity. Administration of oxaliplatin to PC3 and DU145 cells increased NF-kappaB activity, promoting antiapoptotic gene transcription. In addition, oxaliplatin increased the transcription and secretion of CXCL8 and the related CXC-chemokine CXCL1 and increased the transcription and expression of CXC-chemokine receptors, especially CXC-chemokine receptor (CXCR) 2, which transduces the biological effects of CXCL8 and CXCL1. Stimulation of AIPC cells with CXCL8 potentiated NF-kappaB activation in AIPC cells, increasing the transcription and expression of NF-kappaB-regulated antiapoptotic genes of the Bcl-2 and IAP families. Coadministration of a CXCR2-selective antagonist, AZ10397767 (Bioorg Med Chem Lett 18:798-803, 2008), attenuated oxaliplatin-induced NF-kappaB activation, increased oxaliplatin cytotoxicity, and potentiated oxaliplatin-induced apoptosis in AIPC cells. Pharmacological inhibition of NF-kappaBorRNA interference-mediated suppression of Bcl-2 and survivin was also shown to sensitize AIPC cells to oxaliplatin. Our results further support NF-kappaB activity as an important determinant of cancer cell sensitivity to oxaliplatin and identify the induction of autocrine CXCR2 signaling as a novel mode of resistance to this drug.lld:pubmed
pubmed-article:18780829pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18780829pubmed:languageenglld:pubmed
pubmed-article:18780829pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18780829pubmed:citationSubsetIMlld:pubmed
pubmed-article:18780829pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18780829pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18780829pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18780829pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18780829pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18780829pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18780829pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18780829pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18780829pubmed:statusMEDLINElld:pubmed
pubmed-article:18780829pubmed:monthDeclld:pubmed
pubmed-article:18780829pubmed:issn1521-0103lld:pubmed
pubmed-article:18780829pubmed:authorpubmed-author:WilsonCatheri...lld:pubmed
pubmed-article:18780829pubmed:authorpubmed-author:JohnstonPatri...lld:pubmed
pubmed-article:18780829pubmed:authorpubmed-author:WilsonRichard...lld:pubmed
pubmed-article:18780829pubmed:authorpubmed-author:MaxwellPamela...lld:pubmed
pubmed-article:18780829pubmed:authorpubmed-author:O'SullivanJoe...lld:pubmed
pubmed-article:18780829pubmed:authorpubmed-author:SeatonAngelaAlld:pubmed
pubmed-article:18780829pubmed:authorpubmed-author:WaughDavid...lld:pubmed
pubmed-article:18780829pubmed:authorpubmed-author:PurcellColinClld:pubmed
pubmed-article:18780829pubmed:authorpubmed-author:OladipoOlabod...lld:pubmed
pubmed-article:18780829pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18780829pubmed:volume327lld:pubmed
pubmed-article:18780829pubmed:ownerNLMlld:pubmed
pubmed-article:18780829pubmed:authorsCompleteYlld:pubmed
pubmed-article:18780829pubmed:pagination746-59lld:pubmed
pubmed-article:18780829pubmed:meshHeadingpubmed-meshheading:18780829...lld:pubmed
pubmed-article:18780829pubmed:meshHeadingpubmed-meshheading:18780829...lld:pubmed
pubmed-article:18780829pubmed:meshHeadingpubmed-meshheading:18780829...lld:pubmed
pubmed-article:18780829pubmed:meshHeadingpubmed-meshheading:18780829...lld:pubmed
pubmed-article:18780829pubmed:meshHeadingpubmed-meshheading:18780829...lld:pubmed
pubmed-article:18780829pubmed:meshHeadingpubmed-meshheading:18780829...lld:pubmed
pubmed-article:18780829pubmed:meshHeadingpubmed-meshheading:18780829...lld:pubmed
pubmed-article:18780829pubmed:meshHeadingpubmed-meshheading:18780829...lld:pubmed
pubmed-article:18780829pubmed:meshHeadingpubmed-meshheading:18780829...lld:pubmed
pubmed-article:18780829pubmed:meshHeadingpubmed-meshheading:18780829...lld:pubmed
pubmed-article:18780829pubmed:meshHeadingpubmed-meshheading:18780829...lld:pubmed
pubmed-article:18780829pubmed:meshHeadingpubmed-meshheading:18780829...lld:pubmed
pubmed-article:18780829pubmed:meshHeadingpubmed-meshheading:18780829...lld:pubmed
pubmed-article:18780829pubmed:meshHeadingpubmed-meshheading:18780829...lld:pubmed
pubmed-article:18780829pubmed:meshHeadingpubmed-meshheading:18780829...lld:pubmed
pubmed-article:18780829pubmed:meshHeadingpubmed-meshheading:18780829...lld:pubmed
pubmed-article:18780829pubmed:year2008lld:pubmed
pubmed-article:18780829pubmed:articleTitleChemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis.lld:pubmed
pubmed-article:18780829pubmed:affiliationCentre for Cancer Research and Cell Biology, Queens University Belfast, 97 Lisburn Road, Belfast BT9 7BL, UK. d.waugh@qub.ac.uk.lld:pubmed
pubmed-article:18780829pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18780829pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:3576entrezgene:pubmedpubmed-article:18780829lld:entrezgene
entrez-gene:4790entrezgene:pubmedpubmed-article:18780829lld:entrezgene
entrez-gene:3579entrezgene:pubmedpubmed-article:18780829lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18780829lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18780829lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18780829lld:entrezgene
lhgdn:association:7428lhgdn:found_inpubmed-article:18780829lld:lhgdn
lhgdn:association:42546lhgdn:found_inpubmed-article:18780829lld:lhgdn
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18780829lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18780829lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18780829lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18780829lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18780829lld:pubmed